OpenAI Buys Orchestra Bio to Supercharge Its Life Sciences Push
OpenAI is acquiring Orchestra Bio, folding the startup's team and technology into Rosalind, its AI model for life sciences research, and the Rosalind Workbench tool that helps researchers design experiments and analyze results. The deal signals OpenAI's intent to move from general-purpose models into verticalized, workflow-embedded science products. It also puts OpenAI in more direct competition with specialized biotech AI vendors and the pharma companies building in-house.
Orchestra Bio's team and tech will be absorbed into OpenAI's Rosalind life sciences effort
Rosalind Workbench is a harness for experiment planning and results analysis
The acquisition targets AI-powered operations across biopharma R&D workflows